.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Dow
McKesson
Harvard Business School
Healthtrust
Fuji
Cerilliant
Federal Trade Commission
Deloitte
Chubb

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,395,294

« Back to Dashboard

Which drugs does patent 6,395,294 protect, and when does it expire?


Patent 6,395,294 protects TRIESENCE and is included in one NDA.

Summary for Patent: 6,395,294

Title: Method of visualization of the vitreous during vitrectomy
Abstract:A composition for rendering a vitreous cavity visible during a surgical procedure to alleviate a structural disorder caused by the vitreous in an eye, and a method of using the composition. The composition is a vitreous delineating agent that is translucent, opaque or semi-opaque and is in a formulation that may be a solution, a suspension or an emulsion. The agent may be a liposome or microsphere that may additionally contain a therapeutic agent. In use, the agent marks or delineates the vitreous cavity, allowing a surgeon to clearly visualize the entire cavity. Use of the method improves accuracy of a vitrectomy and thus prevents suboptimal outcomes or the need for repeated procedures.
Inventor(s): Peyman; Gholam A. (New Orleans, LA)
Assignee:
Application Number:09/482,779
Patent Claim Types:
see list of patent claims
Composition; Use; Dosage form; Formulation; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms Corp
TRIESENCE
triamcinolone acetonide
INJECTABLE;INTRAVITREAL022048-001Nov 29, 2007RXYesYes6,395,294► SubscribeY USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Citi
Express Scripts
AstraZeneca
Cipla
Harvard Business School
Moodys
UBS
Dow
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot